Breaking News

Cobra Biologics Expands GMP Certification

By Kristin Brooks | February 11, 2014

Quality Control testing and release

Cobra Biologics’ GMP Compliance Certification has been extended to include Quality Control (QC) testing and release of customers’ registered products for in-market supply. The company’s center of excellence for mammalian antibody and recombinant protein production in Södertälje, Sweden, passed an inspection by the Läkemedelsverket (Medical Products Agency) ensuring that the facility complies with the principles and guidelines of GMP as per the Commission Directive 2003/94/EC for Human Medicinal, and Investigational Medicinal, Products.
 
This enhanced certification for biological medicinal products includes the manufacture of active substances by culture of mammalian cells, the storage of both mammalian and microbial cell banks, the release testing of protein for clinical trials, and now the quality control testing of registered products.
 
Peter Coleman, chief executive officer Cobra Biologics, said, “Quality Control testing of registered products is a very important step for Cobra in becoming a recognized commercial supplier of antibodies and recombinant proteins. The future of the company is dependent on us securing commercial product manufacturing and the team have really put in every effort to secure the additional certification.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research